Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company ...

In the fast-paced world of biotech innovation, easy access to crucial resources is vital for research success. That's why Labshares is excited to share news of our partnership with Labviva, a top procurement platform reshaping how scientists obtain l